Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (<scp>NPI</scp>‐0052‐107): final study results
Andrew Spencer, Simon J. Harrison, Jeffrey A. Zonder, Ashraf Badros, Jacob P. Laubach, Krystal Bergin, Amit Khot, Todd M. Zimmerman, Dharminder Chauhan, Nancy K. Levin, Ann MacLaren, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2017). A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (<scp>NPI</scp>‐0052‐107): final study results. , 180(1), DOI: https://doi.org/10.1111/bjh.14987.
Article276 days agoPmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study
Andrew Spencer, Simon J. Harrison, Jacob P. Laubach, Jeffrey A. Zonder, Ashraf Badros, Krystal Bergin, Amit Khot, Todd M. Zimmerman, Kenneth C. Anderson, Ann MacLaren, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2016). Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. , 128(22), DOI: https://doi.org/10.1182/blood.v128.22.3326.3326.
Article276 days agoPhase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma
Andrew Spencer, Jacob P. Laubach, Jeffrey A. Zonder, Ashraf Badros, Simon J. Harrison, Amit Khot, Dharminder Chauhan, Kenneth C. Anderson, Steven D. Reich, Mohit Trikha, Paul G. Richardson (2015). Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. , 126(23), DOI: https://doi.org/10.1182/blood.v126.23.4220.4220.
Article276 days agoA korarchaeal genome reveals insights into the evolution of the Archaea
Iain Anderson, James G. Elkins, Mircea Podar, David E. Graham, Kira S. Makarova, Yuri I. Wolf, Lennart Randau, Brian P. Hedlund, Céline Brochier‐Armanet, Victor Kunin, Iain A. Anderson, Alla Lapidus, Eugene Goltsman, Kerrie Barry, Eugene V Koonin, Philip Hugenholtz, Nikos C. Kyrpides, Gerhard Wanner, Paul G. Richardson, Martín Keller, Karl O. Stetter (2008). A korarchaeal genome reveals insights into the evolution of the Archaea.
Article171 days agoDefibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19
Edward Richardson, Clifton C. Mo, Eleonora Calabretta, Francesco Corrado, Mehmet H. Kocoglu, Rebecca M. Baron, Jean M. Connors, Massimo Iacobelli, L. J. Wei, Emelia Benjamin, Aaron P. Rapoport, Maribel Díaz‐Ricart, Antonio José Martínez-Mellado, Carmelo Carlo‐Stella, Paul G. Richardson, José M. Moraleda (2025). Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19. , 15(7), DOI: https://doi.org/10.3390/biom15071004.
Article21 days ago